Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07217015 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Study acronym: BROADEN2
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites reduced: 68 → 61 locations Eligibility criteria expanded, about 24 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 24 words
  2. Trial status changed: Recruiting → Active, Not Recruiting Study sites: 67 to 68v9 Show 1 more changeShow less
    • Study sites: 67 to 68
  3. Trial sites expanded: 61 → 67 locationsv8
  4. Trial sites expanded: 49 → 61 locationsv7
  5. Trial sites expanded: 31 → 49 locations Eligibility criteria expanded, about 16 wordsv6 Show 1 more changeShow less
    • Eligibility criteria expanded, about 16 words

    See this version in full on ClinicalTrials.gov ↗

Show 4 earlier versionsHide 4 earlier versions
  1. Secondary endpoints revised (12)v5 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 19 to 31v4
  3. Study sites: 10 to 19 Eligibility criteria shortened, about 9 words · Secondary endpoints revised (12)v3 Show 2 more changesShow less
    • Eligibility criteria shortened, about 9 words
    • Secondary endpoints revised (12)

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 2 to 10 Start date changed from estimate of Nov 2025 to Nov 24, 2025v2 Show 1 more changeShow less
    • Start date changed from estimate of Nov 2025 to Nov 24, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.
Trial Details
NCT Number NCT07217015
Lead Sponsor Kymera Therapeutics, Inc.
Conditions Atopic Dermatitis
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov